2.5 Mg Bortezomib Injection IP

Name: 2.5 Mg Bortezomib Injection IP
Brand: NEETCO BIOPHARMA
Price: 1500 INR
Availability: InStock

Price 1500 INR/ Vial

Get a Price/Quote

MOQ : 1 Vial

2.5 Mg Bortezomib Injection IP Specification

Dosage Form
Injection

Salt Composition
Bortezomib 2.5 mg

Indication
Treatment of multiple myeloma and mantle cell lymphoma

Enzyme Types
Proteasome inhibitor

Feature
Sterile, single-use vial

Ingredients
Bortezomib, Mannitol, Nitrogen, Sterile water for injection

Application
Intravenous or subcutaneous administration

Ph Level
Neutral pH (6.5 - 7.5)

Physical Color/Texture
White to off-white lyophilized powder

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits 26S proteasome enzymatic activity

Storage Instructions
Store below 25°C, protect from light

Shelf Life
2 years

Packaging Type
Vial

Usage Restrictions
For hospital and clinical use only

Drug Class
Antineoplastic agent

Concentration
2.5 mg per vial

Brand Name
BORTEZOMIB INJECTION IP

CAS Number
179324-69-7

Prescription Required
Yes

Reconstitution Instructions
Reconstitute with 1.0 to 2.5 ml sterile physiological saline

Molecular Formula
C19H25BN4O4

Route of Administration
IV or SC

USP
Lyophilized powder for reconstitution

About 2.5 Mg Bortezomib Injection IP

Buy Online the elite 2.5 Mg Bortezomib Injection IP, an antineoplastic marvel recommended for the treatment of multiple myeloma and mantle cell lymphoma. This unprecedented pharmaceutical solution, supplied as a lyophilized powder in a distinguished sterile vial, offers affordable access to advanced cancer therapy. With its neutral pH formulation (6.5 - 7.5) and proteasome-inhibiting enzymatic activity, this prescription-required medication ensures reliable patient outcomes. Manufactured for hospital and clinical settings, it is suitable for both intravenous and subcutaneous administration. Secure your vial from India's leading distributor, exporter, supplier, or trader.

Diverse Application for Optimal Results

2.5 Mg Bortezomib Injection IP is exclusively designed for hospital and clinical environments, targeting the treatment of multiple myeloma and mantle cell lymphoma. The injection is administered directly into the bloodstream via intravenous or subcutaneous surfaces, ensuring direct delivery to affected cells. Not intended for plant or surface sanitation, its remarkable efficacy is reserved for healthcare facilities equipped with qualified personnel experienced in cancer therapy. Trust its precise application in elite medical institutions for distinguished patient care.

Seamless Orders, Certifications, and Payment Terms

We offer unrivaled ease in purchasing 2.5 Mg Bortezomib Injection IP online. Payments are accepted through secure terms; available options will be detailed upon inquiry. Certified for medical use and dispatched only to authorized healthcare facilities, this product upholds stringent safety and quality standards. Samples may be available on request, with applicable charges. Our distinguished certifications and streamlined processes ensure you receive a highly dependable and timely solution for your therapeutic requirements.

FAQ's of 2.5 Mg Bortezomib Injection IP:

Q: How is 2.5 Mg Bortezomib Injection IP administered?

A: This injection is administered either intravenously (IV) or subcutaneously (SC) by trained healthcare professionals in a clinical or hospital setting.

Q: What is the primary benefit of using Bortezomib Injection IP?

A: Bortezomib Injection IP acts as a proteasome inhibitor, providing an effective treatment option for patients with multiple myeloma and mantle cell lymphoma.